{"entity":{"id":"nct07181161","kind":"trial","name":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","aka":[],"tldr":"A phase 1/2 trial of Palacaparib in prostate cancer, run by AstraZeneca, now recruiting.","summary":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07181161 by AstraZeneca, with 283 participants planned, started 2025-10-01 and due to reach its primary completion in 2029-01-18. Interventions recorded: AZD0516, AZD9574. Conditions listed: Metastatic Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07181161","url":"https://clinicaltrials.gov/study/NCT07181161"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["palacaparib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07181161","phase":"1/2","setting":"A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer","sponsor":"AstraZeneca","enrolled":283,"outcomes":[]},"route":"/trials/nct07181161/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}